215 related articles for article (PubMed ID: 10807912)
1. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.
Aviel S; Winberg G; Massucci M; Ciechanover A
J Biol Chem; 2000 Aug; 275(31):23491-9. PubMed ID: 10807912
[TBL] [Abstract][Full Text] [Related]
2. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue.
Reinstein E; Scheffner M; Oren M; Ciechanover A; Schwartz A
Oncogene; 2000 Nov; 19(51):5944-50. PubMed ID: 11127826
[TBL] [Abstract][Full Text] [Related]
3. Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity.
Tellam J; Connolly G; Webb N; Duraiswamy J; Khanna R
Blood; 2003 Dec; 102(13):4535-40. PubMed ID: 12920032
[TBL] [Abstract][Full Text] [Related]
4. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
[TBL] [Abstract][Full Text] [Related]
5. TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation.
Greenfeld H; Takasaki K; Walsh MJ; Ersing I; Bernhardt K; Ma Y; Fu B; Ashbaugh CW; Cabo J; Mollo SB; Zhou H; Li S; Gewurz BE
PLoS Pathog; 2015 May; 11(5):e1004890. PubMed ID: 25996949
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
7. Global Proteomic Changes Induced by the Epstein-Barr Virus Oncoproteins Latent Membrane Protein 1 and 2A.
DeKroon RM; Gunawardena HP; Edwards R; Raab-Traub N
mBio; 2018 Jun; 9(3):. PubMed ID: 29921667
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
9. 'ER degradation' of a mutant yeast plasma membrane protein by the ubiquitin-proteasome pathway.
Galan JM; Cantegrit B; Garnier C; Namy O; Haguenauer-Tsapis R
FASEB J; 1998 Mar; 12(3):315-23. PubMed ID: 9506475
[TBL] [Abstract][Full Text] [Related]
10. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
Schubert U; Antón LC; Bacík I; Cox JH; Bour S; Bennink JR; Orlowski M; Strebel K; Yewdell JW
J Virol; 1998 Mar; 72(3):2280-8. PubMed ID: 9499087
[TBL] [Abstract][Full Text] [Related]
11. Degradation of the Id2 developmental regulator: targeting via N-terminal ubiquitination.
Fajerman I; Schwartz AL; Ciechanover A
Biochem Biophys Res Commun; 2004 Feb; 314(2):505-12. PubMed ID: 14733935
[TBL] [Abstract][Full Text] [Related]
12. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitination of the Epstein-Barr virus-encoded latent membrane protein 1 depends on the integrity of the TRAF binding site.
Rothenberger S; Burns K; Rousseaux M; Tschopp J; Bron C
Oncogene; 2003 Aug; 22(36):5614-8. PubMed ID: 12944909
[TBL] [Abstract][Full Text] [Related]
14. RPS27a enhances EBV-encoded LMP1-mediated proliferation and invasion by stabilizing of LMP1.
Hong SW; Kim SM; Jin DH; Kim YS; Hur DY
Biochem Biophys Res Commun; 2017 Sep; 491(2):303-309. PubMed ID: 28735865
[TBL] [Abstract][Full Text] [Related]
15. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.
Izumi KM; Cahir McFarland ED; Riley EA; Rizzo D; Chen Y; Kieff E
J Virol; 1999 Dec; 73(12):9908-16. PubMed ID: 10559303
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitination is required for the retro-translocation of a short-lived luminal endoplasmic reticulum glycoprotein to the cytosol for degradation by the proteasome.
de Virgilio M; Weninger H; Ivessa NE
J Biol Chem; 1998 Apr; 273(16):9734-43. PubMed ID: 9545309
[TBL] [Abstract][Full Text] [Related]
17. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
Gregory MA; Hann SR
Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
[TBL] [Abstract][Full Text] [Related]
18. N-Terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome.
Coulombe P; Rodier G; Bonneil E; Thibault P; Meloche S
Mol Cell Biol; 2004 Jul; 24(14):6140-50. PubMed ID: 15226418
[TBL] [Abstract][Full Text] [Related]
19. Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination.
Staub O; Gautschi I; Ishikawa T; Breitschopf K; Ciechanover A; Schild L; Rotin D
EMBO J; 1997 Nov; 16(21):6325-36. PubMed ID: 9351815
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.
Wilkinson KD
Semin Cell Dev Biol; 2000 Jun; 11(3):141-8. PubMed ID: 10906270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
